Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Hematol
Main Authors: Waller, Cornelius F., Ranganna, Gopinath M., Pennella, Eduardo J., Blakeley, Christopher, Bronchud, Miguel H., Mattano Jr, Leonard A., Berzoy, Oleksandr, Voitko, Nataliia, Shparyk, Yaroslav, Lytvyn, Iryna, Rusyn, Andriy, Popov, Vasil, Láng, István, Beckmann, Katrin, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Barve, Abhijit
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469669/
https://ncbi.nlm.nih.gov/pubmed/30824956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03639-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados